Seaport CMO converts preferred, granted stock options
Seaport Therapeutics Chief Medical Officer Antony Loebel reported equity-related changes in his holdings.
Rhea-AI Filing Summary
Seaport Therapeutics Chief Medical Officer Antony Loebel reported equity-related changes in his holdings. He converted 63,157 shares of Series B Preferred Stock into 20,109 shares of Common Stock on a one‑for‑3.1407 basis, tied to the closing of the company’s initial public offering, and now holds 20,109 common shares directly.
On a separate date, he received a stock option for 63,680 shares of Common Stock at an exercise price of $18.00 per share, expiring on April 29, 2036. These option shares vest in 48 equal monthly installments following April 30, 2026, contingent on his continued service, and represent compensation rather than open‑market trading.
Positive
- None.
Negative
- None.
Insider Trade Summary
63,157 shares exercised/converted
Exercise
3 txns
Insider
Loebel Antony
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Preferred Stock | 63,157 | $0.00 | $0.00 |
| Conversion | Common Stock | 20,109 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 63,680 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 63,680 contracts (Direct);
Series B Preferred Stock — 0 contracts (Direct);
Common Stock — 20,109 shares (Direct)
Footnotes (2)
- F1. Each share of Series B Preferred Stock (the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
- F2. The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Common shares acquired: 20,109 shares
Series B Preferred converted: 63,157 shares
Stock option size: 63,680 shares
+4 more
7 metrics
Common shares acquired
20,109 shares
Common Stock held directly after preferred conversion
Series B Preferred converted
63,157 shares
Converted into 20,109 Common shares at one-for-3.1407
Stock option size
63,680 shares
Stock Option (Right to Buy) granted April 30, 2026
Option exercise price
$18.00 per share
Conversion or exercise price for stock option
Option expiration
April 29, 2036
Expiration date of 63,680-share stock option
Vesting schedule
48 monthly installments
Option vests in equal installments after April 30, 2026
Exercise shares from conversion
63,157 shares
ExerciseShares in transactionSummary for derivative conversion
Key Terms
Conversion of derivative security, Series B Preferred Stock, Stock Option (Right to Buy), initial public offering, +1 more
5 terms
Conversion of derivative security financial
"transaction_code_description: Conversion of derivative security"
Series B Preferred Stock financial
"security_title: Series B Preferred Stock"
Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
initial public offering financial
"automatically converted upon the closing of the Issuer's initial public offering"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
vesting financial
"shall vest in forty-eight (48) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Seaport Therapeutics (SPTX) report for Antony Loebel?
Antony Loebel reported a preferred-to-common conversion and an option grant. He converted 63,157 Series B Preferred shares into 20,109 Common shares and received a stock option covering 63,680 Common shares as equity compensation.
What are the key terms of Antony Loebel’s Seaport Therapeutics (SPTX) stock option grant?
Loebel received an option for 63,680 Seaport Therapeutics common shares. The option has an exercise price of $18.00 per share, expires on April 29, 2036, and vests in 48 equal monthly installments after April 30, 2026, subject to continued service.
Was there any open-market buying or selling by Antony Loebel in this Seaport Therapeutics (SPTX) Form 4?
The Form 4 shows no open-market purchases or sales. It reports a conversion of Series B Preferred Stock into Common Stock and a compensatory stock option grant, both classified as acquisition-type transactions rather than market trades.
How was Seaport Therapeutics (SPTX) Series B Preferred Stock converted in Antony Loebel’s filing?
Each share of Series B Preferred Stock converted into Common Stock on a one‑for‑3.1407 basis. The preferred shares automatically converted into 20,109 common shares upon closing of Seaport Therapeutics’ initial public offering, with no additional consideration required.
AI-generated analysis. How Rhea-AI works. Not financial advice.
